Polymyxins In Veterinary Practice: Essential Guide For 2025

Polymyxins represent a class of polypeptide antibiotics crucial for managing certain bacterial infections in animals, particularly those caused by Gram-negative pathogens. These agents, including polymyxin B and colistin (polymyxin E), have carved a niche in veterinary pharmacology due to their unique mechanism of action and targeted applications.

Understanding the Mechanism of Action

Polymyxins exert their bactericidal effects by binding to lipid components in the outer membranes of Gram-negative bacteria. This interaction disrupts membrane integrity, leading to leakage of cellular contents and rapid cell death. Their affinity for the lipid A portion of lipopolysaccharide (LPS) makes them particularly useful in conditions involving endotoxins, such as in equine cases.

Unlike many other antibiotics, polymyxins do not penetrate cells easily and primarily target extracellular bacteria. This property limits their spectrum but enhances specificity against organisms like Escherichia coli, Pseudomonas aeruginosa, and Salmonella species.

Spectrum of Activity and Synergistic Effects

The activity of polymyxins is predominantly against Gram-negative aerobes. Key susceptible genera include Enterobacter, Klebsiella, Pasteurella, and Bordetella. However, most Proteus and Neisseria strains show natural resistance.

• Effective against: E. coli, Pseudomonas spp., Salmonella spp.
• Limited or resistant: Gram-positive bacteria, Proteus spp.

Polymyxins often synergize with sulfonamides, tetracyclines, and other agents, enhancing overall efficacy in polymicrobial infections. They also neutralize endotoxins, reducing inflammation in septic conditions.

Pharmacokinetics in Animals

Following oral or topical administration, polymyxins exhibit negligible systemic absorption, making them ideal for localized intestinal or surface infections. Parenteral routes yield peak plasma levels within 2 hours, but concentrations remain low due to binding to tissues and exudates. Elimination occurs primarily via kidneys as degraded products, with half-lives of 3-6 hours.

Primary Applications Across Species

Gastrointestinal Infections in Livestock

In poultry and swine production, colistin is widely used orally to combat E. coli-induced enteritis. Formulations like premixes and solutions target intestinal pathogens without significant residue in tissues due to poor absorption.

Endotoxemia in Horses

Polymyxin B is administered intravenously to horses at risk of endotoxemia, often prophylactically before clinical signs manifest. Dosing at 6,000 units/kg every 8 hours binds free LPS, mitigating systemic effects.

Ophthalmic and Topical Uses in Companion Animals

Combination products containing polymyxin B with neomycin or oxytetracycline treat ocular and dermal infections in dogs, cats, and exotic pets. These are applied as ointments or drops for superficial bacterial issues.

• Dogs and cats: Eye/eyelid infections
• Avian species: Off-label ocular therapy
• Small mammals: Skin surface infections

Dosage Guidelines and Administration

Dosages must be tailored to species, condition, and route to balance efficacy and safety. Oral doses for colistin in pigs and poultry range from 50,000-100,000 IU/kg in feed. For equine endotoxemia, polymyxin B is given slowly IV to avoid adverse reactions.

Caution: Extralabel use is common; always consult veterinary guidelines. Not approved for oral/parenteral in all US species.

Toxicity Concerns and Contraindications

Systemic use is restricted due to nephrotoxicity, neurotoxicity, and neuromuscular blockade risks. High doses can cause injection-site pain, histamine release, or hypersensitivity.

• Nephrotoxic: Monitor renal function in prolonged therapy
• Neurotoxic: Avoid in myasthenia gravis-like conditions
• Inhibitors: Divalent cations, fatty acids reduce efficacy

In veterinary settings, topical and oral routes minimize these risks, preserving polymyxins as viable options.

Resistance Trends and Stewardship

While intrinsic chromosomal resistance exists, plasmid-mediated resistance is rising, especially in veterinary isolates. In Europe, colistin use in food animals ranks high, prompting reevaluation amid human MDR concerns.

Resistance rates: <1% in healthy animals, up to 10% in pathogenic porcine E. coli. Zoonotic transfer risks underscore the need for judicious use.

Veterinary stewardship involves:

• Limiting to confirmed susceptible infections
• Avoiding growth promotion
• Combining with susceptibility testing

Clinical Considerations and Monitoring

Success depends on early intervention, pathogen identification, and MIC-guided therapy. Post-antibiotic effects are limited, so combination regimens may be needed for high-inoculum infections.

For endotoxemia, preemptive dosing maximizes LPS neutralization.

Future Directions in Veterinary Polymyxin Use

With MDR Gram-negatives surging, polymyxins remain vital, but optimized dosing and alternatives are researched. EMA recommends reserving for serious cases with few options.

Veterinarians play a key role in preserving efficacy through antimicrobial stewardship programs.

Frequently Asked Questions (FAQs)

What animals commonly receive polymyxins?

Poultry, pigs, horses, dogs, cats, and exotics for GI, endotoxic, or topical infections.

Are polymyxins safe for systemic use?

Limited due to toxicity; prefer topical/oral routes.

How does resistance to polymyxins develop?

Primarily chromosomal, increasingly plasmid-mediated via animal overuse.

Can polymyxins treat eye infections?

Yes, in combinations for dogs, cats, birds.

What is the role in endotoxemia?

Binds LPS in horses, best pre-symptomatically.